E
MIRM icon

Ergoteles’s Mirum Pharmaceuticals MIRM Stock Holding History

Ergoteles’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,012
Closed -$289K – 1310
2023
Q1 		$289K Buy
+12,012
New +$274K 0.01% 912
2021
Q3 		– Sell
-11,000
Closed -$190K – 1497
2021
Q2 		$190K Buy
+11,000
New +$197K ﹤0.01% 1299

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ergoteles's MIRM Position: Q2 2023 in Review

Ergoteles sold out of Mirum Pharmaceuticals (MIRM) in Q2 2023, closing a stake of 12,012 shares — an estimated $289K sold.

Ergoteles first reported a position in MIRM in Q2 2021 and held it in 2 quarters. The position peaked at $289K in Q1 2023. 146 funds tracked by Wall St. Rank hold MIRM as of Q2 2023.

  • Ergoteles reported no remaining Mirum Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 12,012 Mirum Pharmaceuticals shares in Q2 2023, an estimated $289K.
  • Ergoteles first reported a position in Mirum Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Mirum Pharmaceuticals position peaked at $289K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.